CAJ | 학술논문

目的：观察玻璃体腔注射雷珠单抗联合激光光凝治疗视网膜分支静脉阻塞（ branch retinal vein occlusion ， BRVO）合并黄斑水肿的疗效和安全性。 　　方法：据荧光素眼底血管造影（ FFA ）对BRVO合并黄斑水肿患者30例30眼随机分为3组：第1组（10眼）单纯行黄斑区格栅样光凝；第2组（10眼）玻璃体腔注射1次雷珠单抗0．05mL／0．5mg，7d后行黄斑区格栅样光凝；第3组（10眼）玻璃体腔连续注射3次雷珠单抗0．05mL／0．5mg，间隔1mo，第1次注射7d 后行黄斑区格栅样光凝。随访6 mo ，观察最佳矫正视力及OCT检查（干涉光断层扫描仪检查）黄斑中央厚度。 　　结果：患者6 mo后视力显著提高，1组平均提高11个字母，2组提高17个字母，3组提高18个字母。 OCT显示1组黄斑中央厚度平均降低208．7μm，2组降低312.9μm，3组降低326．8μm。1组中视力提高3行以上1例（10％），2组有3例（30％），3组有4例（40％）。 　　结论：联合治疗明显优于单独激光治疗，雷珠单抗1次玻璃体腔内注射联合黄斑区格栅样激光光凝术治疗BRVO并黄斑水肿安全有效。
목적：관찰파리체강주사뢰주단항연합격광광응치료시망막분지정맥조새（ branch retinal vein occlusion ， BRVO）합병황반수종적료효화안전성。 　　방법：거형광소안저혈관조영（ FFA ）대BRVO합병황반수종환자30례30안수궤분위3조：제1조（10안）단순행황반구격책양광응；제2조（10안）파리체강주사1차뢰주단항0．05mL／0．5mg，7d후행황반구격책양광응；제3조（10안）파리체강련속주사3차뢰주단항0．05mL／0．5mg，간격1mo，제1차주사7d 후행황반구격책양광응。수방6 mo ，관찰최가교정시력급OCT검사（간섭광단층소묘의검사）황반중앙후도。 　　결과：환자6 mo후시력현저제고，1조평균제고11개자모，2조제고17개자모，3조제고18개자모。 OCT현시1조황반중앙후도평균강저208．7μm，2조강저312.9μm，3조강저326．8μm。1조중시력제고3행이상1례（10％），2조유3례（30％），3조유4례（40％）。 　　결론：연합치료명현우우단독격광치료，뢰주단항1차파리체강내주사연합황반구격책양격광광응술치료BRVO병황반수종안전유효。
AIM: To observe the safety and efficacy of intravitreal injection of ranibizumab combined with laser photocoagulation for the treatment of macular edema in branch retinal vein occlusion ( BRVO) . METHODS: According to fundus fluorescein angiography ( FFA ) , 30 eyes of 30 patients with BRVO were randomized into three groups: group 1 ( 10 eyes ) received grid laser treatment alone, group 2 received a single dose of intravitreal injection of ranibizumab (0.05mL/0.5mg) followed by grid laser treatment on 7d following injection, while group 3 ( 10 eyes ) received three loading doses of intravitreal ranibizumab with 0.05mL/0.5mg for three times.At 1mo interval, grid laser treatment was performed after 7d of the 1st injection.After 6mo follow-up, the best-corrected visual acuity and optical coherence tomography ( OCT ) and central macular thickness were observed. RESULTS:After 6mo, the visual acuity of patients were improved significantly.There was an average increase of 11 letters, 17 letters and 18 letters in group 1, 2, and 3, respectively, with the average decrease in OCT being 208.7μm, 312.9μm and 326.8μm, respectively, in these groups.Gain in visual acuity more than 3 lines was 1 case ( 10%) in group 1.There were 3 cases ( 30%) in group 2 and 4 cases (40%) in group 3. CONCLUSION:Combined therapy is better than laser therapy alone. Single dose of intravitreal ranibizumab with grid laser for macular edema in BRVO seems to be effective.